These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11598313)

  • 1. Treatment of Alzheimer's disease with clioquinol.
    Regland B; Lehmann W; Abedini I; Blennow K; Jonsson M; Karlsson I; Sjögren M; Wallin A; Xilinas M; Gottfries CG
    Dement Geriatr Cogn Disord; 2001; 12(6):408-14. PubMed ID: 11598313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
    Ritchie CW; Bush AI; Mackinnon A; Macfarlane S; Mastwyk M; MacGregor L; Kiers L; Cherny R; Li QX; Tammer A; Carrington D; Mavros C; Volitakis I; Xilinas M; Ames D; Davis S; Beyreuther K; Tanzi RE; Masters CL
    Arch Neurol; 2003 Dec; 60(12):1685-91. PubMed ID: 14676042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clioquinol treatment in familiar early onset of Alzheimer's disease: a case report.
    Ibach B; Haen E; Marienhagen J; Hajak G
    Pharmacopsychiatry; 2005 Jul; 38(4):178-9. PubMed ID: 16025421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metal protein attenuating compounds for the treatment of Alzheimer's disease.
    Sampson E; Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2008 Jan; (1):CD005380. PubMed ID: 18254079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes.
    Di Vaira M; Bazzicalupi C; Orioli P; Messori L; Bruni B; Zatta P
    Inorg Chem; 2004 Jun; 43(13):3795-7. PubMed ID: 15206857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents.
    Domingo JL
    J Alzheimers Dis; 2006 Nov; 10(2-3):331-41. PubMed ID: 17119296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clioquinol for the treatment of Alzheimer's Disease.
    Jenagaratnam L; McShane R
    Cochrane Database Syst Rev; 2006 Jan; (1):CD005380. PubMed ID: 16437529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The solution structure of the copper clioquinol complex.
    Pushie MJ; Nienaber KH; Summers KL; Cotelesage JJ; Ponomarenko O; Nichol HK; Pickering IJ; George GN
    J Inorg Biochem; 2014 Apr; 133():50-6. PubMed ID: 24503514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metal chelation therapy for Alzheimer disease.
    Rosenberg RN
    Arch Neurol; 2003 Dec; 60(12):1678-9. PubMed ID: 14676040
    [No Abstract]   [Full Text] [Related]  

  • 10. Understanding Alzheimer's Disease and its Metal Chelation Therapeutics: A Narrative Review.
    Thakur R; Karwasra R; Umar T
    Curr Pharm Des; 2023; 29(30):2377-2386. PubMed ID: 37859328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
    Faux NG; Ritchie CW; Gunn A; Rembach A; Tsatsanis A; Bedo J; Harrison J; Lannfelt L; Blennow K; Zetterberg H; Ingelsson M; Masters CL; Tanzi RE; Cummings JL; Herd CM; Bush AI
    J Alzheimers Dis; 2010; 20(2):509-16. PubMed ID: 20164561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AβPP/PS1 transgenic mouse brain.
    Wang T; Wang CY; Shan ZY; Teng WP; Wang ZY
    J Alzheimers Dis; 2012; 29(3):549-59. PubMed ID: 22269164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol.
    Mao F; Yan J; Li J; Jia X; Miao H; Sun Y; Huang L; Li X
    Org Biomol Chem; 2014 Aug; 12(31):5936-44. PubMed ID: 24986600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.
    Mancino AM; Hindo SS; Kochi A; Lim MH
    Inorg Chem; 2009 Oct; 48(20):9596-8. PubMed ID: 19817493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
    Moret V; Laras Y; Pietrancosta N; Garino C; Quéléver G; Rolland A; Mallet B; Norreel JC; Kraus JL
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3298-301. PubMed ID: 16581247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease.
    Robert A; Liu Y; Nguyen M; Meunier B
    Acc Chem Res; 2015 May; 48(5):1332-9. PubMed ID: 25946460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease.
    Kessler H; Pajonk FG; Meisser P; Schneider-Axmann T; Hoffmann KH; Supprian T; Herrmann W; Obeid R; Multhaup G; Falkai P; Bayer TA
    J Neural Transm (Vienna); 2006 Nov; 113(11):1763-9. PubMed ID: 16736242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process.
    Sjögren M; Davidsson P; Gottfries J; Vanderstichele H; Edman A; Vanmechelen E; Wallin A; Blennow K
    Dement Geriatr Cogn Disord; 2001; 12(4):257-64. PubMed ID: 11351137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.
    Grossi C; Francese S; Casini A; Rosi MC; Luccarini I; Fiorentini A; Gabbiani C; Messori L; Moneti G; Casamenti F
    J Alzheimers Dis; 2009; 17(2):423-40. PubMed ID: 19363260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.